Table 15.
The diagnostic performance of MRI-PDFF and CAP for liver steatosis in patients with NAFLD [296]
| Method | No. of studies | No. of patients | AUC | Cutoff value | Sensitivity% (95% CI) | Specificity% (95% CI) | PLR% (95% CI) | NLR% (95% CI) |
|---|---|---|---|---|---|---|---|---|
| Mild steatosis (≥S1) | ||||||||
| MRI-PDFF | 6 | 667 | 0.97 | 5.36 | 92.0 (87.0–95.0) | 93.0 (90.0–96.0) | 14.16 (8.97–22.35) | 0.08 (0.05–0.14) |
| CAP | 11 | 1,893 | 0.85 | 273.58 | 82.0 (79.0–84.0) | 83.0 (80.0–86.0) | 4.41 (2.84–6.86) | 0.28 (0.21–0.37) |
| M-probe | 5 | 548 | 0.96 | 254.4 | 88.0 (83.0–92.0) | 92.0 (88.0–95.0) | 7.32 (3.54–15.15) | 0.14 (0.10–0.21) |
| XL-probe | 4 | 450 | 0.8 | 300 | 69.0 (57.0–78.0) | 82.0 (68.0–91.0) | 3.61 (1.86–7.03) | 0.38 (0.27–0.54) |
| Moderate steatosis (≥S2) | ||||||||
| MRI-PDFF | 9 | 969 | 0.91 | 15.36 | 79.0 (72.0–85.0) | 88.0 (84.0–91.0) | 6.54 (4.88–8.76) | 0.25 (0.18–0.33) |
| CAP | 18 | 3,295 | 0.83 | 288.5 | 81.0 (79.0–83.0) | 63.0 (61.0–65.0) | 2.40 (1.96–2.93) | 0.29 (0.25–0.34) |
| M-probe | 11 | 1,433 | 0.84 | 283.21 | 82.0 (77.0–86.0) | 66.0 (55.0–76.0) | 2.66 (1.90–3.71) | 0.28 (0.22–0.34) |
| XL-probe | 6 | 730 | 0.84 | 297.43 | 94.0 (84.0–98.0) | 57.0 (40.0–72.0) | 2.08 (1.45–2.98) | 0.25 (0.15–0.40) |
| Severe steatosis (≥S3) | ||||||||
| MRI-PDFF | 8 | 804 | 0.90 | 20.35 | 71.0 (62.0–79.0) | 89.0 (86.0–92.0) | 6.35 (4.76–8.48) | 0.33 (0.25–0.45) |
| CAP | 17 | 2,835 | 0.79 | 309.09 | 79.0 (77.0–81.0) | 56.0 (53.0–58.0) | 2.12 (1.75–2.58) | 0.36 (0.31–0.43) |
| M-probe | 10 | 1,336 | 0.75 | 299.77 | 85.0 (75.0–92.0) | 57.0 (47.0–66.0) | 1.85 (1.56–2.20) | 0.32 (0.23–0.45) |
| XL-probe | 6 | 730 | 0.80 | 325.71 | 79.0 (72.0–84.0) | 62.0 (47.0–75.0) | 2.36 (1.74–3.20) | 0.33 (0.26–0.42) |
MRI-PDFF, MRI-proton density fat fraction; CAP, controlled attenuation parameter; NAFLD, nonalcoholic fatty liver disease; AUC, area under the curve; CI, confidence interval; PNR, positive likelihood ratio; NLR, negative likelihood ratio.